AgomAb Therapeutics NV
AGMB- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002020932
In the last 90 days, AgomAb Therapeutics NV insiders filed 7 open-market purchases and 0 sales; 34 institutions reported holding it in 13F filings for Q2 2026, worth $337.0M in total; no superinvestor holds it.
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysLast 90 days, $592.1K in total
- 7
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +2 vs. previous quarter
- 34
- 13F valueReported value at the end of Q2 2026
- $337.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 920.9K
- Shares sold short
- Change
- −21.1K
- −2.2% vs. previous
- Days to cover
- 7.44
- At average daily volume
Superinvestors holding AGMB, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding AGMB at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by AgomAb Therapeutics NV insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 16, 2026 (view filing)6:43 AM ET | Nov 13 | 3 days | Epstein David RDirector | PPurchase | +15.0K | $5.92 | +$88.7K | +37.5%55.0K after | 4 lots |
| Nov 6, 2026 (view filing)6:39 AM ET | Nov 5 | 1 day | Epstein David RDirector | PPurchase | +15.0K | $6.90 | +$103.5K | +60.0%40.0K after | 3 lots |
| Oct 22, 2026 (view filing)8:14 AM ET | Oct 21 | 1 day | Epstein David RDirector | PPurchase | +10.0K | $8.88 | +$88.8K | +66.7%25.0K after | 2 lots |
| Oct 9, 2026 (view filing)8:01 AM ET | Oct 8 | 1 day | Epstein David RDirector | PPurchase | +5.00K | $8.90 | +$44.5K | +50.0%15.0K after | |
| Oct 7, 2026 (view filing)8:57 AM ET | Oct 5-6 | 2 days | Epstein David RDirector | PPurchase | +10.0K | $8.64 | +$86.3K | New position10.0K after | 2 lots |
| Oct 7, 2026 (view filing)8:47 AM ET | Oct 6 | 1 day | Kemula Pierre Thadee VictorChief Financial Officer | PPurchase | +10.0K | $8.59 | +$85.9K | New position10.0K after | 3 lots |
| Oct 7, 2026 (view filing)8:06 AM ET | Oct 5-6 | 2 days | Knotnerus Tim JasperChief Executive Officer | PPurchase | +11.0K | $8.58 | +$94.4K | +101.6%21.8K after | 2 lots |
Top 10 13F holders, Q2 2026
See all 34 holdersThe largest institutional positions in AgomAb Therapeutics NV at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,141,992 | $66.7M | 7.74% | 00.0% | Unchanged |
| Sanofi | 2,783,096 | $36.1M | 6.76% | 00.0% | Unchanged |
| Redmile Group, LLC | 2,733,926 | $35.5M | 2.38% | +2,577,676+1,649.7% | Added |
| Cormorant Asset Management, LP | 2,465,348 | $32.0M | 1.64% | 00.0% | Unchanged |
| TCG Crossover Management, LLC | 2,053,233 | $26.7M | 0.64% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 1,618,000 | $21.0M | 0.03% | 00.0% | Unchanged |
| Nantahala Capital Management, LLC | 1,568,188 | $20.4M | 1.23% | +368,188+30.7% | Added |
| Casdin Capital, LLC | 1,550,000 | $20.1M | 1.01% | 00.0% | Unchanged |
| Andera Partners | 1,538,702 | $20.0M | 9.67% | 00.0% | Unchanged |
| FMR LLC | 1,458,677 | $18.9M | 0.00% | 00.0% | Unchanged |
Holders of 5% or more of AGMB
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of AgomAb Therapeutics NV.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| LSP 7 Cooperative UA | 13D | 10.60%5.14M shares | New | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| FMR LLC | 13G | 10.00%4.87M shares | New | Mar 6, 20261 filing | Mar 6, 2026 | SEC |
| Pontifax Management 4 G.P. (2015) Ltd. | 13G | 6.80%3.31M shares | New | Apr 16, 20261 filing | Apr 16, 2026 | SEC |
| Sanofi | 13G | 5.71%2.78M shares | New | May 6, 20261 filing | May 6, 2026 | SEC |
| Cormorant Asset Management, LP | 13G | 5.01%2.47M shares | New | May 15, 20261 filing | May 15, 2026 | SEC |